Last reviewed · How we verify
sumatriptan succinate/naproxen sodium
Sumatriptan is a 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release, while naproxen is an NSAID that inhibits prostaglandin synthesis to reduce inflammation and pain.
Sumatriptan is a 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release, while naproxen is an NSAID that inhibits prostaglandin synthesis to reduce inflammation and pain. Used for Acute migraine with or without aura.
At a glance
| Generic name | sumatriptan succinate/naproxen sodium |
|---|---|
| Also known as | Treximet, Treximet (TM) |
| Sponsor | GlaxoSmithKline |
| Drug class | 5-HT1B/1D receptor agonist combined with NSAID |
| Target | 5-HT1B receptor, 5-HT1D receptor, COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Sumatriptan selectively activates serotonin 5-HT1B and 5-HT1D receptors on cranial blood vessels and trigeminal nerve terminals, causing vasoconstriction and reducing the release of inflammatory neuropeptides involved in migraine pathophysiology. Naproxen sodium inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin production and providing additional anti-inflammatory and analgesic effects. The combination targets both the vascular and inflammatory components of migraine.
Approved indications
- Acute migraine with or without aura
Common side effects
- Chest pain or pressure
- Dizziness
- Nausea
- Paresthesia
- Gastrointestinal upset
- Flushing
Key clinical trials
- Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks (PHASE3)
- TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine (PHASE3)
- An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate) (PHASE1)
- Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents (PHASE3)
- A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) (PHASE3)
- A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) (PHASE3)
- Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA) (PHASE3)
- Migraine Study in Adolescent Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sumatriptan succinate/naproxen sodium CI brief — competitive landscape report
- sumatriptan succinate/naproxen sodium updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI